Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index; 72 of the 132 sources its claims cite were checked for support.

Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial

Open access

Published version of a preprint

Abstract

Background: A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical efficacy of psilocybin-assisted therapy when incorporated as an auxiliary intervention during inpatient rehabilitation for severe alcohol use disorder. Moreover, it intends to pinpoint the modifications in the two core neurocognitive systems underscored by dual-process models of addiction. Methods: In this double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial, 62 participants aged 21–64 years will be enrolled to undergo psilocybin-assisted therapy as part of a 4-week inpatient rehabilitation for severe alcohol use disorder. The experimental group will receive a high dose of psilocybin (30 mg), whereas the control group will receive an active placebo dose of psilocybin (5 mg), both within the context of a brief standardized psychotherapeutic intervention drawing from key elements of acceptance and commitment therapy. The primary clinical outcome is the between-group difference regarding the change in percentage of heavy drinking days from baseline to four weeks posthospital discharge, while safety and feasibility metrics will also be reported as primary outcomes. Key secondary assessments include between-group differences in terms of changes in (1) drinking behavior parameters up to six months posthospital discharge, (2) symptoms of depression, anxiety, trauma, and global functioning, (3) neuroplasticity and key neurocognitive mechanisms associated with addiction, and (4) psychological processes and alcohol-related parameters. Discussion: The discussion outlines issues that might arise from our design. Trial registration: EudraCT 2022-002369-14 and NCT06160232. © 2024, The Author(s).

Overview

CoChat Summary

## TL;DR

This paper is a protocol for a double-blind, randomized, placebo-controlled phase II superiority trial testing whether a single 30 mg dose of psilocybin, delivered with brief psychotherapy during inpatient rehabilitation, improves outcomes for severe alcohol use disorder (sAUD) versus a 5 mg active placebo. It also aims to measure feasibility, safety, blinding, and proposed neurocognitive and psychological mechanisms over a 7-month follow-up.

## Key findings

  • The trial will enroll 62 participants aged 21–64 years with severe alcohol use disorder and randomize them 1:1 to 30 mg psilocybin vs 5 mg psilocybin (active placebo) during a 4-week inpatient rehabilitation program.
  • The primary clinical outcome is the between-group difference in change in percentage of heavy drinking days from baseline to 4 weeks posthospital discharge; the paper states the sample-size calculation targeted n = 46 for this analysis and increased to n = 62 to allow for 25% attrition.
  • The study will also report feasibility and safety as primary outcomes, including inclusion and retention rates and systematic adverse-event recording.
  • The protocol’s hypotheses are that the high-dose group will have a greater reduction in heavy drinking days and better alcohol-related, psychological, and neurocognitive outcomes, while serious adverse reactions will not differ between groups.

## Methods

  • Design: Monocentric, double-blind, randomized, placebo-controlled, 1:1 parallel-group, 7-month phase II superiority trial at the Psychiatry Department of Brugmann University Hospital.
  • Sample/data: 62 participants with sAUD, ages 21–64, undergoing a 4-week alcohol detoxification program; the intervention is 30 mg psilocybin vs 5 mg psilocybin active placebo, each embedded in a brief standardized psychotherapy protocol drawing from ACT.
  • Analysis: The plan is to use intention-to-treat analyses for clinical outcomes, mixed-model ANOVA for continuous outcomes, general linear mixed models for time series with missing data, and chi-squared or Fisher’s exact tests for adverse events; mediation analyses will examine whether mechanistic variables explain treatment effects.

## Limitations

  • The paper states that using a low yet psychoactive 5 mg active placebo may still produce therapeutic effects and may fail to maintain blinding; it also may reduce between-group effect sizes.
  • The authors state that the trial’s strict inclusion and exclusion criteria limit how representative the sample can be, even though the study is intended to be pragmatic.
  • Evident from the protocol: this is a protocol paper, so it reports planned outcomes and methods rather than trial results.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12888-024-05502-y

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

48 Valid · 3 Not valid · 25 Not checked · 15 Own results and interpretations

41 more claims · 24 with their cited sources checked

Create a free account to see all 91 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 32

Create a free account to see these claims.

Citations

Cites

Show all 121 references

Research works printed but not linked: 1

  1. Spielberger CD. Manual for the state-trait anxiety inventory (self-Evaluation questionnaire). Palo Alto, CA: Consulting Psychologists Press; 1983.

Cited by

See all 13

Metadata

Authors
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., Mallet, L., Leys, C., & Noël, X.
Affiliations
  • Université Libre de Bruxelles (BE)
  • Centre National de la Recherche Scientifique (FR)
  • Inserm (FR)
  • Centre Hospitalier Universitaire Brugmann (BE)
  • University of Geneva (CH)
Corresponding author
Vanderijst, Laetitia
Venue
BMC Psychiatry
Published
2024-01-26
Volume
24
Issue
1
Pages
77-77
ISSN
1471-244X (ISSN-L)
OpenAlex
W4391256257
Cited by
13
References
121
Citations by year
2026: 6 · 2025: 7
FWCI
6.48
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fonds De La Recherche Scientifique - FNRS (40010687)
  • Fonds Iris-Recherche (2023-J1820690-232470)
  • Brugmann Foundation (2022-10)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
psilocybin-assisted therapy, alcoholism, severe alcohol use disorder, neuroplasticity, heavy drinking days, anxiety and depressive symptoms, trauma symptoms, global functioning, acceptance and commitment therapy, active placebo, treatment safety and feasibility
MeSH terms
Equivalence Trials as Topic, Alcohol Drinking, Alcoholism, Double-Blind Method, Humans, Psilocybin, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Acceptance and Commitment Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. https://app.cochat.ai/papers/10.1186/s12888-024-05502-y
The paper
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., Mallet, L., Leys, C., & Noël, X. (2024). Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. BMC Psychiatry. https://doi.org/10.1186/s12888-024-05502-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.